CAR T-cell therapy in a clinical trial for relapsed or refractory AL amyloidosis
Early Results for CAR T-Cell Therapy in Relapsed or Refractory AL Amyloidosis
Initial early results were seen for the use of chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory amyloid light-chain (AL) amyloidosis in the NEXICART-2 trial.
First-Ever U.S. Trial of CAR T-Cell Therapy for Relapsed/Refractory AL Amyloidosis
For the first time, researchers in the U.S. have been able to study the use of CAR T-cell therapy for patients with relapsed/refractory (R/R) AL amyloidosis.
How one retired Cleveland Clinic physician found hope after her own rare disease diagnosis
The retired Cleveland Clinic physician said years of practicing internal medicine taught her that serious illness could be overwhelming.
Share Your Rare Disease Journey
The article profiled Emily Whitehead, a girl diagnosed with acute lymphoblastic leukemia at five years old, who became the first child to receive CAR T-cell therapy.
A Lincoln woman battled a rare disease for 10 years. How she found health and joy
At her eldest daughter’s 2014 wedding in Galt, Lisa Ferrero wore a strapless navy dress and served as the maid of honor. Recently divorced and living alone, she had been working out regularly and felt healthy and confident as she walked down the aisle.
Immix Biopharma (NASDAQ: IMMX)
Immix Biopharma is a clinical-stage biopharma developing personalized therapies for oncology and immunology. Lead asset NXC-201 is a BCMA-targeting CAR-T asset, being evaluated for amyloid light chain amyloidosis and multiple myeloma, with plans to expand to autoimmune indications.
CAR T Cell Therapy for Light Chain (AL) Amyloidosis Achieves Strong Results
MSK cellular therapist Dr. Heather Landau led a phase 1 clinical trial showing CAR T cell therapy is effective against relapsed or resistant AL amyloidosis. “I’ve seen very sick patients have an amazing recovery in a short time,” she says.